Cited by 574Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Efficacy and safety of degludec versus glargine in type 2 diabetes.

Open access

Marso, Steven P., McGuire, Darren K., Zinman, Bernard, Poulter, Neil R., Emerson, Scott S., Pieber, Thomas R., Pratley, Richard E., Haahr, Poul-Martin, Lange, Martin, Brown-Frandsen, Kirstine, Moses, Alan, Skibsted, Simon, Kvist, Kajsa, Buse, John B.·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1615692PMC PMC5731244

Open this paper in CoChat — free account

Abstract

BACKGROUND: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS: We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-to-target, event-driven cardiovascular outcomes trial. The primary composite outcome in the time-to-event analysis was the first occurrence of an adjudicated major cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) with a prespecified noninferiority margin of 1.3. Adjudicated severe hypoglycemia, as defined by the American Diabetes Association, was the prespecified, multiplicity-adjusted secondary outcome. RESULTS: Of the patients who underwent randomization, 6509 (85.2%) had established cardiovascular disease, chronic kidney disease, or both. At baseline, the mean age was 65.0 years, the mean duration of diabetes was 16.4 years, and the mean (±SD) glycated hemoglobin level was 8.4±1.7%; 83.9% of the patients were receiving insulin. The primary outcome occurred in 325 patients (8.5%) in the degludec group and in 356 (9.3%) in the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P<0.001 for noninferiority). At 24 months, the mean glycated hemoglobin level was 7.5±1.2% in each group, whereas the mean fasting plasma glucose level was significantly lower in the degludec group than in the glargine group (128±56 vs. 136±57 mg per deciliter, P<0.001). Prespecified adjudicated severe hypoglycemia occurred in 187 patients (4.9%) in the degludec group and in 252 (6.6%) in the glargine group, for an absolute difference of 1.7 percentage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for superiority). Rates of adverse events did not differ between the two groups. CONCLUSIONS: Among patients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of major cardiovascular events. (Funded by Novo Nordisk and others; DEVOTE ClinicalTrials.gov number, NCT01959529 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1615692

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
(2013) · JAMA · doi:10.1001/jama.2013.281053 · Cited by 30,732
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471

Show all 27 references

Research works printed but not linked: 2

2001, J Postgrad Med, 47, 199
Wysham C, 2016, Diabetologia, 59, S43. abstract

Sorted by citations

Items 101–200 of 572

Association of severe hypoglycemia with mortality for people with diabetes mellitus during a 20-year follow-up in Denmark: a cohort study
Jensen, M. H., Dethlefsen, C., Hejlesen, O. K., & Vestergaard, P. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01447-x · Cited by 41
Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
Vargas‐Uricoechea, H. (2018) · Journal of Diabetes Research · doi:10.1155/2018/2052101 · Cited by 39
Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018
Peralta, F. G., Escalada, J., Torre, E. L. M., Mata‐Cases, M., García, J. C. F., Loiola, P. E., Lachica, L. Á., Pérez, J. A. F., Menéndez, S. A., Guisasola, F. Á., et al. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.004 · Cited by 46
Insulin and Its Cardiovascular Effects: What Is the Current Evidence?
Dongerkery, S. P., Schroeder, P. R., & Shomali, M. E. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0955-3 · Cited by 38
The promising future of insulin therapy in diabetes mellitus
Cheng, R., Taleb, N., Stainforth-Dubois, M., & RABASA-LHORET, R. P. R. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00608.2020 · Cited by 37
How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with type 1 diabetes?
Livingstone, R., Boyle, J. G., & Petrie, J. R. (2020) · Diabetic Medicine · doi:10.1111/dme.13911 · Cited by 34
Lipidization as a tool toward peptide therapeutics
Myšková, A., Sýkora, D., Kuneš, J., & Maletı́nská, L. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2284685 · Cited by 36
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
Valentine, V., Goldman, J. D., & Shubrook, J. H. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0287-y · Cited by 35
Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes
Heller, S. R., Buse, J. B., Ratner, R. E., Seaquist, E. R., Bardtrum, L., Hansen, C. T., Tutkunkardas, D., & Moses, A. C. (2019) · Diabetes Care · doi:10.2337/dc18-2361 · Cited by 33
Self-citation
Telestroke Across the Continuum of Care: Lessons from the COVID-19 Pandemic
Guzik, A. K., Martin‐Schild, S., Tadi, P. K. R., Chapman, S., Kasab, S. A., Martini, S. R., Meyer, B. C., Demaerschalk, B. M., Wozniak, M. A., & Southerland, A. M. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105802 · Cited by 33
A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
Nuffer, W. A., Guesnier, A., & Trujillo, J. M. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817752315 · Cited by 33
Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Self-citation
Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 32
Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes
Aktürk, H. K., Rewers, A. H., Joseph, H., Schneider, N., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0114 · Cited by 32
PROFILING OF CLINICAL DYNAMICS OF TYPE 2 DIABETES MELLITUS IN PATIENTS: A PERSPECTIVE REVIEW
Ikwuka, A. O., Omoju, D. I., & Mahanera, O. K. (2023) · World Journal of Current Medical and Pharmaceutical Research · doi:10.37022/wjcmpr.v5i5.294 · Cited by 45
Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation
Owens, D. R., Bailey, T. S., Fanelli, C. G., Yale, J., & Bolli, G. B. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.11.004 · Cited by 34
Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)
Amod, A., Buse, J. B., McGuire, D. K., Pieber, T. R., Pop‐Busui, R., Pratley, R. E., Zinman, B., Hansen, M. B., Jia, T., Mark, T., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00715-x · Cited by 34
Self-citation
Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials
Liu, W., Yang, X., & Huang, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8726046 · Cited by 32
2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 30
Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables
Cavaiola, T. S., Kiriakov, Y., & Reid, T. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.015 · Cited by 31
Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Tentolouris, A., Eleftheriadou, I., Tzeravini, E., Tsilingiris, D., Paschou, S. Α., Siasos, G., & Tentolouris, N. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190119154152 · Cited by 31
Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition
Akoumianakis, I., Badi, I., Douglas, G., Chuaiphichai, S., Herdman, L., Akawi, N. A., Margaritis, M., Antonopoulos, A. S., Oikonomou, E. K., Psarros, C. T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8824 · Cited by 31
Review of Associations Between Type 2 Diabetes and Cancer
Bonagiri, P. R., & Shubrook, J. H. (2020) · Clinical Diabetes · doi:10.2337/cd19-0077 · Cited by 32
Evidence-Based Management of Diabetes in Older Adults
Mooradian, A. D. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0598-3 · Cited by 31
Comparison of insulin glargine 300 U/ mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
Yamabe, M., Kuroda, M., Hirosawa, Y., Kamino, H., Ohno, H., & Yoneda, M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12894 · Cited by 29
Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO , a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia
Goldenberg, R., Aroda, V. R., Billings, L. K., Christiansen, A. S. L., Donatsky, A. M., Rizi, E. P., Podgorski, G., Rašlová, K., Klonoff, D. C., & Bergenstal, R. M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14504 · Cited by 29
Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes
Razavi-Nematollahi, L., & Ismail‐Beigi, F. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1266-7 · Cited by 31
Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives
Khunti, K., Hassanein, M. M., Lee, M., Mohan, V., & Amod, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00833-x · Cited by 32
Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: A prospective study
Fadini, G. P., Feher, M., Hansen, T. K., de Valk, H. W., Koefoed, M. M., Wolden, M., Zimmermann, E., & Jendle, J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01021 · Cited by 27
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Leung, K., Mansell, K. D., & Simpson, S. H. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.002 · Cited by 32
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
Scheen, A. J. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104158 · Cited by 29
Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care
Mehta, R., Goldenberg, R., Katselnik, D., & Kuritzky, L. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1925148 · Cited by 29
Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy
Goldenberg, R., & Berard, L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1372118 · Cited by 27
Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis
Cai, X., Gao, X., Yang, W., & Ji, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1400011 · Cited by 26
Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
Berard, L., Antonishyn, N., Arcudi, K., Blunden, S., CHENG, A. Y. Y., Goldenberg, R., Harris, S. B., Jones, S., Mehan, U., Morrell, J., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0375-7 · Cited by 25
Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
Zhou, W., Tao, J., Zhou, X., & Chen, H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0624-4 · Cited by 26
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
Reifsnider, O. S., Kansal, A. R., Gandhi, P., Cragin, L. S., Brand, S. B., Pfarr, E., Fahrbach, K. R., & Ustyugova, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001313 · Cited by 28
Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
Pratley, R. E., Husain, M., Lingvay, I., Pieber, T. R., Mark, T., Saevereid, H. A., Møller, D. V., Zinman, B., & the DEVOTE Study Group (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0960-8 · Cited by 25
Self-citation
Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes—A Proposed MARE Definition
Prischl, F. C., & Wanner, C. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.04.008 · Cited by 27
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Lalic, K. S., Škrha, J., Valensi, P. E., & Ceriello, A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0667-2 · Cited by 25
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin
Alexopoulos, A., & Buse, J. B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.012 · Cited by 25
Self-citation
Glycaemic control in people with diabetes following acute myocardial infarction
Esdaile, H., Hill, N. E., Mayet, J., & Oliver, N. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110644 · Cited by 28
Pharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 23
Comparative effectiveness and harms of long‐acting insulins for type 1 and type 2 diabetes: A systematic review and meta‐analysis
Holmes, R. S., Crabtree, E. A., & McDonagh, M. S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13614 · Cited by 23
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future
Retnakaran, R. R., & Zinman, B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14552 · Cited by 23
Self-citation
Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
Ko, S., Hur, K. Y., Rhee, S. Y., Kim, N. H., Moon, M. K., Park, S.-O., Lee, B., Kim, H. J., Choi, K. M., & Kim, J. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.298 · Cited by 23
Therapie des Typ-2-Diabetes
Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 23
Hypoglycaemia and its management in primary care setting
Ibrahim, M., Baker, J., Cahn, A., Eckel, R. H., El Sayed, N. A., Fischl, A. H., Gaede, P., Leslie, R. D., Pieralice, S., Tuccinardi, D., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3332 · Cited by 21
Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes
McCoy, R. G., SWARNA, K. S., Deng, Y., Herrin, J. S., Ross, J. S., Kent, D. M., Borah, B. J., Crown, W. H., Montori, V. M., Umpierrez, G. E., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100852 · Cited by 22
2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
Comparison of Mortality and Major Cardiovascular Events Among Adults With Type 2 Diabetes Using Human vs Analogue Insulins
Neugebauer, R. S., Schroeder, E. B., Reynolds, K., Schmittdiel, J. A., Loes, L., Dyer, W., DESAI, J. R., Vazquez‐Benitez, G., Ho, P. M., Anderson, J. P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18554 · Cited by 22
Tratamento farmacológico da hiperglicemia no DM2
Filho, R. L. D. S., Albuquerque, L., Cavalcanti, S. M., Tambascia, M. A., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-10 · Cited by 33
Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478)
Philis‐Tsimikas, A., STRATTON, I. M., Troelsen, L. N., Bak, B. A., & Leiter, L. A. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819841585 · Cited by 22
Therapie des Typ-2-Diabetes
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1193-3793 · Cited by 22
Trends in medication utilization, glycemic control and outcomes among type 2 diabetes patients in a tertiary referral center in Singapore from 2007 to 2017
Tan, Y. Z., Cheen, M. H. H., Goh, S., Bee, Y. M., Lim, P. S., Khee, G. Y., & Thumboo, J. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12886 · Cited by 23
Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
Hinton, W., Feher, M. D., Munro, N. M., Walker, M., & de Lusignan, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13710 · Cited by 19
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
Hinnen, D. A., & Kruger, D. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188705 · Cited by 23
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
Harris, S. B., Abrahamson, M. J., Ceriello, A., Charpentier, G., Evans, M., Lehmann, R., Liebl, A., Linjawi, S., Holt, R. I. G., Hosszúfalusi, N., et al. (2020) · Drugs · doi:10.1007/s40265-019-01245-3 · Cited by 21
The safety and efficacy of second-generation basal insulin analogues in adults with type 2 diabetes at risk of hypoglycemia and use in other special populations: A narrative review
Cheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
Pratley, R. E., Emerson, S. S., Franek, E., Gilbert, M. P., Marso, S. P., McGuire, D. K., Pieber, T. R., Zinman, B., Hansen, C. T., Hansen, M. V., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13699 · Cited by 20
Self-citation
The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus
Pollock, R. F., Norrbacka, K., Boye, K. S., Osumili, B., & Valentine, W. J. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2035132 · Cited by 20
Insulin degludec in the first trimester of pregnancy: Report of two cases
Milluzzo, A., Tumminia, A., Scalisi, N. M., Frittitta, L., Vigneri, R., & Sciacca, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12721 · Cited by 20
Practical Approaches to Diagnosing, Treating and Preventing Hypoglycemia in Diabetes
Kreider, K. E., Pereira, K. C., & Padilla, B. I. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0325-9 · Cited by 20
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 22
The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes
Pasquel, F. J., Gregg, E. W., & Ali, M. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.11.001 · Cited by 20
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
Brown‐Frandsen, K., Emerson, S. S., McGuire, D. K., Pieber, T. R., Poulter, N. R., Pratley, R. E., Zinman, B., Ranthe, M. F., Grøn, R., Lange, M., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13677 · Cited by 18
Self-citation
EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021)
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 19
Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine u100: Results from switch 2
Heller, S. R., DeVries, J. H., Wysham, C., Hansen, C. T., Hansen, M. V., & Frier, B. M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13708 · Cited by 18
Empagliflozin, metformin and insulin degludec, during pregnancy: a case report
Formoso, G., Ginestra, F., Di Dalmazi, G., & Consoli, A. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1134-y · Cited by 18
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18
Self-citation
IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy
Miller, E. M., Doshi, A., Grøn, R., Jódar, E., Örsy, P., Ranthe, M. F., Sugimoto, D. H., Tentolouris, N., Viljoen, A., & Billings, L. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13851 · Cited by 18
DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs
Wang, W., Agner, B. F. R., Luo, B., Liu, L., Liu, M. R., Peng, Y., Qu, S., Stachlewska, K., Wang, G., Yuan, G., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13286 · Cited by 18
Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes
Henao, D. C., Múñoz, Ó., Gómez, A. M., Rondón, M., Colon, C. A., Chica, L. G., Rubio, C., Vargas, F. M. L., Calvachi, M. A., & Perea, A. M. (2018) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2018.03.003 · Cited by 18
Diabetes mellitus y riesgo cardiovascular. Actualización de las recomendaciones del Grupo de Trabajo de Diabetes y Riesgo Cardiovascular de la Sociedad Española de Diabetes (SED, 2018)
Arrieta, F., Iglesias, P., Pedro‐Botet, J., Becerra, A., Ortega, E., Obaya, J. C., Nubiola, A., Maldonado, G. F., Campos, M. D. M., Petrecca, R., et al. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.03.002 · Cited by 18
Development of a liver‐specific Tet‐off AAV8 vector for improved safety of insulin gene therapy for diabetes
Gan, S. U., Fu, Z., Sia, K. C., Kon, O. L., Calne, R., & Lee, K. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3067 · Cited by 18
Hypoglycaemia leads to a delayed increase in platelet and coagulation activation markers in people with type 2 diabetes treated with metformin only: Results from a stepwise hypoglycaemic clamp study
Aberer, F., Pferschy, P. N., Tripolt, N. J., Sourij, C., Obermayer, A. M., Prüller, F., Novak, E., Reitbauer, P., Kojzar, H., Prietl, B., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13889 · Cited by 18
Update on Management of Type 2 Diabetes for Cardiologists
Qureshi, M., Gammoh, E., Shakil, J., & Robbins, R. J. (2018) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-14-4-273 · Cited by 17
Hypoglycemia in Older Patients
Hoogwerf, B. J. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.04.001 · Cited by 19
Diabetes subtypes classification for personalized health care: A review
Omar, N., Nazirun, N. N. N., Vijayam, B., Wahab, A. A., & Bahuri, H. A. (2022) · Artificial Intelligence Review · doi:10.1007/s10462-022-10202-8 · Cited by 17
Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy
Galis, P., Bartosova, L., Farkašová, V., Barteková, M., Ferenczyová, K., & Rajtík, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1451100 · Cited by 19
Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1
Bergenstal, R. M., Ásbjörnsdóttir, B., Watt, S. K., Lingvay, I., Mader, J. K., Nishida, T., & Rosenstock, J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00220-1 · Cited by 18
Diabetes and cardiovascular disease: from new mechanisms to new therapies
Gajos, G. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4227 · Cited by 17
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922
Owens, D. R., Monnier, L., Ceriello, A., & Bolli, G. B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14587 · Cited by 17
Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE
Heller, S. R., Lingvay, I., Marso, S. P., Philis‐Tsimikas, A., Pieber, T. R., Poulter, N. R., Pratley, R. E., HACHMANN-NIELSEN, E., Kvist, K., Lange, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14208 · Cited by 16
Self-citation
Type 2 diabetes and cardiovascular prevention: the dogmas disputed
Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2017) · Endocrine · doi:10.1007/s12020-017-1418-y · Cited by 16
Insulin glargine 300 U/ mL and insulin degludec: A review of the current evidence comparing these two second‐generation basal insulin analogues
CHENG, A. Y. Y., Bailey, T. S., Mauricio, D., & Roussel, R. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3329 · Cited by 16
One‐year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes
Taybani, Z. J., Bótyik, B., Gyimesi, A., Katkó, M., & Várkonyi, T. T. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.390 · Cited by 15
Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis
Visolyi, G. Á., Domján, B. A., Svébis, M. M., Péterfi, A., Lovasz, B. D., Mészáros, S., Horváth, V. J., & Tabák, Á. G. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.03.002 · Cited by 16
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Jerkins, T. W., McGill, J. B., & Bell, D. S. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15062 · Cited by 19
Lessons for modern insulin development
Herring, R. A., & Russell-Jones, D. L. (2018) · Diabetic Medicine · doi:10.1111/dme.13692 · Cited by 16
Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update
Peralta, F. G., Martín, F. J. E. S., Torre, E. L. M., Mata‐Cases, M., García, J. C. F., Loiola, P. E., Lachica, L. Á., Pérez, J. A. F., Menéndez, S. A., Guisasola, F. Á., et al. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.11.010 · Cited by 16
Personalized Management of Type 2 Diabetes
Peter, P. R., & Lupsa, B. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1244-0 · Cited by 16
Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Katsiki, N., Kotsa, K., Stoian, A. P., & Mikhailidis, D. P. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200909142658 · Cited by 16
Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions
Lefever, E., Vliebergh, J., & Mathieu, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1856813 · Cited by 16
Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes
Chatterjee, S., Khunti, K. K., & Davies, M. J. (2019) · Drugs · doi:10.1007/s40265-018-1048-6 · Cited by 15
Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review
Ahmed, R., de Souza, R. J., Li, V., Banfield, L. E., & Anand, S. S. (2024) · Diabetologia · doi:10.1007/s00125-023-06052-w · Cited by 16
Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
Vilsbøll, T., Blevins, T., Jódar, E., Poulter, N. R., Tentolouris, N., Agner, B. F. R., Lehmann, L., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13675 · Cited by 15
Self-citation
Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy
Haldrup, S., Lapolla, A., Gundgaard, J., & Wolden, M. L. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1669613 · Cited by 16

Authors: Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., Moses, A., Skibsted, S., Kvist, K., & Buse, J. B.
Affiliations: Mount Sinai Hospital (CA)
University of North Carolina at Chapel Hill (US)
ORCID: McGuire, Darren K.
Zinman, Bernard
Poulter, Neil R.
Emerson, Scott S.
Pieber, Thomas R.
Pratley, Richard E.
Lange, Martin
Kvist, Kajsa
Buse, John B.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-08-24
Volume: 377
Issue: 8
Pages: 723-732
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1615692
PMC: PMC5731244
OpenAlex: W2625031949
Cited by: 574
References: 27
Citations by year: 2026: 20 · 2025: 16 · 2024: 41 · 2023: 43 · 2022: 56 · 2021: 61 · 2020: 81 · 2019: 104 · 2018: 100 · 2017: 50
FWCI: 72.47
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
Acibadem University Open Access Repository (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
Versus Arthritis (20639, 18475)
National Institutes of Health (UL1TR001111, UL1TR002489)
National Institute of Diabetes and Digestive and Kidney Diseases (T35DK060444, P30DK020541)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: insulin degludec, insulin glargine, type 2 diabetes, basal insulin, cardiovascular safety, major adverse cardiovascular events, severe hypoglycemia, HbA1c, fasting blood glucose, non-inferiority, cardiovascular disease, chronic kidney disease, glycemic variability, insulin duration of action
MeSH terms: Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Incidence, Insulin, Long-Acting, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and safety of degludec versus glargine in type 2 diabetes.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks